{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T12:26:53Z","timestamp":1693139213778},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T00:00:00Z","timestamp":1347408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Ovarian cancer is a heterogeneous disease and prognosis for apparently similar cases of ovarian cancer varies. Recurrence of the disease in early stage (FIGO-stages I-II) serous ovarian cancer results in survival that is comparable to those with recurrent advanced-stage disease. The aim of this study was to investigate if there are specific genomic aberrations that may explain recurrence and clinical outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Fifty-one women with early stage serous ovarian cancer were included in the study. DNA was extracted from formalin fixed samples containing tumor cells from ovarian tumors. Tumor samples from thirty-seven patients were analysed for allele-specific copy numbers using OncoScan single nucleotide polymorphism arrays from Affymetrix and the bioinformatic tool Tumor Aberration Prediction Suite. Genomic gains, losses, and loss-of-heterozygosity that associated with recurrent disease were identified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The most significant differences (p\u2009&lt;\u20090.01) in Loss-of-heterozygosity (LOH) were identified in two relatively small regions of chromosome 19; 8.0-8,8\u2009Mbp (19 genes) and 51.5-53.0\u2009Mbp (37 genes). Thus, 56 genes on chromosome 19 were potential candidate genes associated with clinical outcome. LOH at 19q (51-56\u2009Mbp) was associated with shorter disease-free survival and was an independent prognostic factor for survival in a multivariate Cox regression analysis. In particular LOH on chromosome 19q (51-56\u2009Mbp) was significantly (p\u2009&lt;\u20090.01) associated with loss of TP53 function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The results of our study indicate that presence of two aberrations in TP53 on 17p and LOH on 19q in early stage serous ovarian cancer is associated with recurrent disease. Further studies related to the findings of chromosomes 17 and 19 are needed to elucidate the molecular mechanism behind the recurring genomic aberrations and the poor clinical outcome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-407","type":"journal-article","created":{"date-parts":[[2012,9,12]],"date-time":"2012-09-12T08:14:02Z","timestamp":1347437642000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease"],"prefix":"10.1186","volume":"12","author":[{"given":"Ingiridur","family":"Skirnisdottir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Mayrhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Ryd\u00e5ker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"\u00c5kerud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Isaksson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,9,12]]},"reference":[{"key":"3380_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","volume":"116","author":"JK Chan","year":"2010","unstructured":"Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, Bell J: Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2010, 116: 307-311. 10.1016\/j.ygyno.2009.10.074.","journal-title":"Gynecol Oncol"},{"key":"3380_CR2","doi-asserted-by":"publisher","first-page":"e232","DOI":"10.1371\/journal.pmed.0050232","volume":"5","author":"M K\u00f6bel","year":"2008","unstructured":"K\u00f6bel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D: Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008, 5: e232-10.1371\/journal.pmed.0050232.","journal-title":"PLoS Med"},{"key":"3380_CR3","first-page":"4722","volume":"62","author":"DR Schwartz","year":"2002","unstructured":"Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG, Misek DE, Wu R, Zhai Y, Darrah DM, Reed H, Ellenson LH, Giordano TJ, Fearon ER, Hanash SM, Cho KR: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002, 62: 4722-4729.","journal-title":"Cancer Res"},{"key":"3380_CR4","doi-asserted-by":"publisher","first-page":"10602","DOI":"10.1158\/0008-5472.CAN-05-2240","volume":"65","author":"T Bonome","year":"2005","unstructured":"Bonome T, Lee J-Y, Park D-C, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ: Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005, 65: 10602-10612. 10.1158\/0008-5472.CAN-05-2240.","journal-title":"Cancer Res"},{"key":"3380_CR5","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-04-2398","volume":"11","author":"A Berchuck","year":"2005","unstructured":"Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005, 11: 3686-3696. 10.1158\/1078-0432.CCR-04-2398.","journal-title":"Clin Cancer Res"},{"key":"3380_CR6","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1371\/journal.pmed.1000025","volume":"6","author":"K Lawrenson","year":"2009","unstructured":"Lawrenson K, Gayther SA: Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med. 2009, 6: e25-10.1371\/journal.pmed.1000025.","journal-title":"PLoS Med"},{"key":"3380_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2009.04.002","volume":"114","author":"J Chien","year":"2009","unstructured":"Chien J, Fan J-B, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC: Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol. 2009, 114: 3-11. 10.1016\/j.ygyno.2009.04.002.","journal-title":"Gynecol Oncol"},{"key":"3380_CR8","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","volume":"164","author":"I-M Shih","year":"2004","unstructured":"Shih I-M, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004, 164: 1511-1518. 10.1016\/S0002-9440(10)63708-X.","journal-title":"Am J Pathol"},{"key":"3380_CR9","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/1078-0432.CCR-08-2430","volume":"15","author":"A Berchuck","year":"2009","unstructured":"Berchuck A, Iversen ES, Luo J, Clarke JP, Horne H, Levine DA, Boyd J, Alonso MA, Secord AA, Bernardini MQ, Barnett JC, Boren T, Murphy SK, Dressman HK, Marks JR, Lancaster JM: Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clin Cancer Res. 2009, 15: 2448-2455. 10.1158\/1078-0432.CCR-08-2430.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"3380_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0020-7292(03)90118-4","volume":"83","author":"AP Heintz","year":"2003","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S: Carcinoma of the ovary. Int J Gynaecol Obstet. 2003, 83 (Suppl 1): 135-166.","journal-title":"Int J Gynaecol Obstet"},{"key":"3380_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ygyno.2009.09.029","volume":"116","author":"M K\u00f6bel","year":"2010","unstructured":"K\u00f6bel M, Kalloger SE, Santos JL, Huntsman DG, Gilks CB, Swenerton KD: Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2010, 116: 50-56. 10.1016\/j.ygyno.2009.09.029.","journal-title":"Gynecol Oncol"},{"key":"3380_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ygyno.2003.08.034","volume":"91","author":"H Lassus","year":"2003","unstructured":"Lassus H, Leminen A, Lundin J, Lehtovirta P, Butzow R: Distinct subtypes of serous ovarian carcinoma identified by p53 determination. Gynecol Oncol. 2003, 91: 504-512. 10.1016\/j.ygyno.2003.08.034.","journal-title":"Gynecol Oncol"},{"key":"3380_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ygyno.2010.01.048","volume":"117","author":"KM Darcy","year":"2010","unstructured":"Darcy KM, Birrer MJ: Translational research in the gynecologic oncology group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010, 117: 429-439. 10.1016\/j.ygyno.2010.01.048.","journal-title":"Gynecol Oncol"},{"key":"3380_CR14","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.2006.09.0795","volume":"25","author":"MJ Birrer","year":"2007","unstructured":"Birrer MJ, Johnson ME, Hao K, Wong K-K, Park D-C, Bell A, Welch WR, Berkowitz RS, Mok SC: Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007, 25: 2281-2287. 10.1200\/JCO.2006.09.0795.","journal-title":"J Clin Oncol"},{"key":"3380_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s13273-011-0011-3","volume":"7","author":"JY Kwon","year":"2011","unstructured":"Kwon JY, Seo YR, Ahn WS: Recognition of potential predictive markers for diagnosis in Korean serous ovarian cancer patients at stage IIIc using array comparative genomic hybridization with high resolution. Mol Cell Toxicolo. 2011, 7: 77-86. 10.1007\/s13273-011-0011-3.","journal-title":"Mol Cell Toxicolo"},{"key":"3380_CR16","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/gb-2011-12-10-r108","volume":"12","author":"M Rasmussen","year":"2011","unstructured":"Rasmussen M, Sundstr\u00f6m M, Kultima HG, Botling J, Micke P, Birgisson H, Glimelius B, Isaksson A: Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 2011, 12: R108-10.1186\/gb-2011-12-10-r108.","journal-title":"Genome Biol"},{"key":"3380_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00109-008-0419-y","volume":"87","author":"S Lassmann","year":"2009","unstructured":"Lassmann S, Kreutz C, Schoepflin A, Hopt U, Timmer J, Werner M: A novel approach for reliable microarray analysis of microdissected tumor cells from formalin-fixed and paraffin-embedded colorectal cancer resection specimens. J Mol Med. 2009, 87: 211-224. 10.1007\/s00109-008-0419-y.","journal-title":"J Mol Med"},{"key":"3380_CR18","first-page":"741","volume":"27","author":"I Sk\u00edrnisd\u00f3ttir","year":"2012","unstructured":"Sk\u00edrnisd\u00f3ttir I, Seidal T: The apoptosis regulators p53, bax and PUMA: relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment. Oncol Rep. 2012, 27: 741-747.","journal-title":"Oncol Rep"},{"key":"3380_CR19","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/IGC.0b013e31820986e5","volume":"21","author":"IA Sk\u00edrnisd\u00f3ttir","year":"2011","unstructured":"Sk\u00edrnisd\u00f3ttir IA, Sorbe B, Lindborg K, Seidal T: Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011, 21: 236-244. 10.1097\/IGC.0b013e31820986e5.","journal-title":"Int J Gynecol Cancer"},{"key":"3380_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1097\/IGC.0b013e31821dc906","volume":"21","author":"I Sk\u00edrnisd\u00f3ttir","year":"2011","unstructured":"Sk\u00edrnisd\u00f3ttir I, Seidal T: Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer. Int J Gynecol Cancer. 2011, 21: 1024-1031. 10.1097\/IGC.0b013e31821dc906.","journal-title":"Int J Gynecol Cancer"},{"key":"3380_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","volume":"95","author":"JB Trimbos","year":"2003","unstructured":"Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst. 2003, 95: 113-125. 10.1093\/jnci\/95.2.113.","journal-title":"J Natl Cancer Inst"},{"key":"3380_CR22","unstructured":"WMA Declaration of Helsinki - Ethical principles for medical research involving human subjects. http:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/index.html."},{"key":"3380_CR23","unstructured":"Affymetrix research services laboratory. http:\/\/www.affymetrix.com\/products_services\/services\/."},{"key":"3380_CR24","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/bioinformatics\/btl646","volume":"23","author":"ES Venkatraman","year":"2007","unstructured":"Venkatraman ES, Olshen AB: A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics. 2007, 23: 657-663. 10.1093\/bioinformatics\/btl646.","journal-title":"Bioinformatics"},{"issue":"9251","key":"3380_CR25","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S0140-6736(00)03590-X","volume":"357","author":"I Vergote","year":"2001","unstructured":"Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verrelst H, Sj\u00f6vall K, Timmerman D, Vandewalle J, Van Gramberen M, Trop\u00e9 CG: Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001, 357 (9251): 176-182. 10.1016\/S0140-6736(00)03590-X.","journal-title":"Lancet"},{"key":"3380_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/ncponc1178","volume":"5","author":"PA Konstantinopoulos","year":"2008","unstructured":"Konstantinopoulos PA, Spentzos D, Cannistra SA: Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol. 2008, 5: 577-587. 10.1038\/ncponc1178.","journal-title":"Nat Clin Pract Oncol"},{"key":"3380_CR27","doi-asserted-by":"publisher","first-page":"e11408","DOI":"10.1371\/journal.pone.0011408","volume":"5","author":"KL Gorringe","year":"2010","unstructured":"Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DDL: Australian ovarian cancer study: copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS ONE. 2010, 5: e11408-10.1371\/journal.pone.0011408.","journal-title":"PLoS ONE"},{"key":"3380_CR28","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1158\/1078-0432.CCR-08-1564","volume":"15","author":"D Etemadmoghadam","year":"2009","unstructured":"Etemadmoghadam D, DeFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew Y-E, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D: Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Canc Res. 2009, 15: 1417-1427. 10.1158\/1078-0432.CCR-08-1564.","journal-title":"Clin Canc Res"},{"key":"3380_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"D Bell","year":"2011","unstructured":"Bell D, Berchuck A, Birrer M, et al: Integrated genomic analyses of ovarian carcinoma. Nature. 2011, 474: 609-615. 10.1038\/nature10166.","journal-title":"Nature"},{"key":"3380_CR30","doi-asserted-by":"publisher","first-page":"e28503","DOI":"10.1371\/journal.pone.0028503","volume":"6","author":"KO Wrzeszczynski","year":"2011","unstructured":"Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R: Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE. 2011, 6: e28503-10.1371\/journal.pone.0028503.","journal-title":"PLoS ONE"},{"key":"3380_CR31","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/gcc.20694","volume":"48","author":"KL Gorringe","year":"2009","unstructured":"Gorringe KL, Ramakrishna M, Williams LH, Sridhar A, Boyle SE, Bearfoot JL, Li J, Anglesio MS, Campbell IG: Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis. Genes Chromosomes Cancer. 2009, 48: 931-942. 10.1002\/gcc.20694.","journal-title":"Genes Chromosomes Cancer"},{"key":"3380_CR32","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1158\/1078-0432.CCR-07-0502","volume":"13","author":"KL Gorringe","year":"2007","unstructured":"Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DYH, Campbell IG: High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin Cancer Res. 2007, 13: 4731-4739. 10.1158\/1078-0432.CCR-07-0502.","journal-title":"Clin Cancer Res"},{"key":"3380_CR33","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/bioinformatics\/17.12.1228","volume":"17","author":"M Baudis","year":"2001","unstructured":"Baudis M: Progenetix.net: an online repository for molecular cytogenetic aberration data. Bioinformatics. 2001, 17: 1228-1229. 10.1093\/bioinformatics\/17.12.1228.","journal-title":"Bioinformatics"},{"key":"3380_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010, 221: 49-56. 10.1002\/path.2696.","journal-title":"J. Pathol"},{"key":"3380_CR35","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1006\/gyno.1997.4709","volume":"66","author":"A Bicher","year":"1997","unstructured":"Bicher A, Ault K, Kimmelman A, Gershenson D, Reed E, Liang B: Loss of heterozygosity in human ovarian cancer on chromosome 19q. Gynecologic Oncology. 1997, 66: 36-40. 10.1006\/gyno.1997.4709.","journal-title":"Gynecologic Oncology"},{"key":"3380_CR36","unstructured":"The human protein atlas. http:\/\/www.proteinatlas.org\/."},{"key":"3380_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/leu.2009.187","volume":"24","author":"R Gunnarsson","year":"2009","unstructured":"Gunnarsson R, Isaksson A, Mansouri M, G\u00f6ransson H, Jansson M, Cahill N, Rasmussen M, Staaf J, Lundin J, Norin S, Buhl AM, Smedby KE, Hjalgrim H, Karlsson K, Jurlander J, Juliusson G, Rosenquist R: Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Leukemia. 2009, 24: 211-215.","journal-title":"Leukemia"},{"key":"3380_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1097-2765(01)00213-1","volume":"7","author":"J Yu","year":"2001","unstructured":"Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001, 7: 673-682. 10.1016\/S1097-2765(01)00213-1.","journal-title":"Mol Cell"},{"key":"3380_CR39","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ygyno.2008.08.020","volume":"111","author":"KM Darcy","year":"2008","unstructured":"Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnoila RI, Hendricks D, Bonome T, Farley JH: Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers a gynecologic oncology group study. Gynecol Oncol. 2008, 111: 487-495. 10.1016\/j.ygyno.2008.08.020.","journal-title":"Gynecol Oncol"},{"key":"3380_CR40","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0304-3835(03)00344-6","volume":"199","author":"MO Hoque","year":"2003","unstructured":"Hoque MO, Begum S, Sommer M, Lee T, Trink B, Ratovitski E, Sidransky D: PUMA in head and neck cancer. Cancer Lett. 2003, 199: 75-81. 10.1016\/S0304-3835(03)00344-6.","journal-title":"Cancer Lett"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-407\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-407.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:30:11Z","timestamp":1630614611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3380"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-407","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,12]]},"assertion":[{"value":"9 May 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"407"}}